{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:48:40Z","timestamp":1780321720694,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41440-024-01848-8","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T04:03:16Z","timestamp":1723780996000},"page":"2961-2963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Do angiotensin-converting enzyme inhibitors not reduce the risk of pneumonia?"],"prefix":"10.1038","volume":"47","author":[{"given":"Shunichiro","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"1848_CR1","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/S0140-6736(10)61459-6","volume":"377","author":"O Ruuskanen","year":"2011","unstructured":"Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264\u201375.","journal-title":"Lancet"},{"key":"1848_CR2","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s12325-020-01248-7","volume":"37","author":"J Ferreira-Coimbra","year":"2020","unstructured":"Ferreira-Coimbra J, Sarda C, Rello J. Burden of community-acquired pneumonia and unmet clinical needs. Adv Ther. 2020;37:1302\u201318.","journal-title":"Adv Ther"},{"key":"1848_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1056\/NEJMra1714562","volume":"380","author":"LA Mandell","year":"2019","unstructured":"Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019;380:651\u201363.","journal-title":"N Engl J Med"},{"key":"1848_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jgf2.532","volume":"23","author":"H Tsunoda","year":"2022","unstructured":"Tsunoda H, Okami Y, Honda Y, Shiroshita A, Kataoka Y, Tsujimoto Y, et al. Effectiveness of angiotensin converting enzyme inhibitors in preventing pneumonia: a systematic review and meta-analysis. J Gen Fam Med. 2022;23:217\u201327.","journal-title":"J Gen Fam Med"},{"key":"1848_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/phar.2739","volume":"42","author":"DP Alexander","year":"2022","unstructured":"Alexander DP, Nickman NA, Chhibber A, Stoddard GJ, Biskupiak JE, Munger MA. Angiotensin-converting enzyme inhibitors reduce community-acquired pneumonia hospitalization and mortality. Pharmacotherapy. 2022;42:890\u20137.","journal-title":"Pharmacotherapy"},{"key":"1848_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/FPC.0b013e328341041c","volume":"21","author":"A Grilo","year":"2011","unstructured":"Grilo A, S\u00e1ez-Rosas MP, Santos-Morano J, S\u00e1nchez E, Moreno-Rey C, Real LM, et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genom. 2011;21:10\u20137.","journal-title":"Pharmacogenet Genom"},{"key":"1848_CR7","doi-asserted-by":"publisher","first-page":"e4260","DOI":"10.1136\/bmj.e4260","volume":"345","author":"D Caldeira","year":"2012","unstructured":"Caldeira D, Alarc\u00e3o J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345:e4260.","journal-title":"BMJ"},{"key":"1848_CR8","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1097\/HJH.0b013e328357a87a","volume":"30","author":"CL Liu","year":"2012","unstructured":"Liu CL, Shau WY, Wu CS, Lai MS. Angiotensin-converting enzyme inhibitor\/angiotensin II receptor blockers and pneumonia risk among stroke patients. J Hypertens. 2012;30:2223\u20139.","journal-title":"J Hypertens"},{"key":"1848_CR9","doi-asserted-by":"publisher","unstructured":"Uemura R, Hieda M, Maeda M, Murata F, Fukuda H. Risk of pneumonia-related hospitalization after initiating angiotensin-converting enzyme inhibitors compared with angiotensin II receptor blockers: a retrospective cohort study using LIFE Study data. Hypertens Res. 2024. https:\/\/doi.org\/10.1038\/s41440-024-01768-7. Epub ahead of print.","DOI":"10.1038\/s41440-024-01768-7"},{"key":"1848_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41440-022-00922-3","volume":"45","author":"Y Matsuzawa","year":"2022","unstructured":"Matsuzawa Y, Kimura K, Ogawa H, Tamura K. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19. Hypertens Res. 2022;45:1147\u201353.","journal-title":"Hypertens Res"},{"key":"1848_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u20133.","journal-title":"Nature"},{"key":"1848_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380.e8.","journal-title":"Cell"},{"key":"1848_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/path.2987","volume":"225","author":"RM W\u00f6sten-van Asperen","year":"2011","unstructured":"W\u00f6sten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol. 2011;225:618\u201327.","journal-title":"J Pathol"},{"key":"1848_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155236","volume":"133","author":"J Shin","year":"2022","unstructured":"Shin J, Toyoda S, Nishitani S, Onodera T, Fukuda S, Kita S, et al. SARS-CoV-2 infection impairs the insulin\/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. Metabolism. 2022;133:155236.","journal-title":"Metabolism"},{"key":"1848_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1042\/CS20201511","volume":"135","author":"MA Pedrosa","year":"2021","unstructured":"Pedrosa MA, Valenzuela R, Garrido-Gil P, Labandeira CM, Navarro G, Franco R, et al. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci. 2021;135:465\u201381.","journal-title":"Clin Sci"},{"key":"1848_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","volume":"9","author":"A Bauer","year":"2021","unstructured":"Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021;9:863\u201372.","journal-title":"Lancet Respir Med"},{"key":"1848_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96294-8","volume":"11","author":"S Tsukamoto","year":"2021","unstructured":"Tsukamoto S, Wakui H, Azushima K, Yamaji T, Urate S, Suzuki T, et al. Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease. Sci Rep. 2021;11:16843.","journal-title":"Sci Rep"},{"key":"1848_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100962","volume":"37","author":"M Duarte","year":"2021","unstructured":"Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:100962.","journal-title":"EClinicalMedicine"},{"key":"1848_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","volume":"43","author":"Y Matsuzawa","year":"2020","unstructured":"Matsuzawa Y, Ogawa H, Kimura K, Konishi M, Kirigaya J, Fukui K, et al. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertens Res. 2020;43:1257\u201366.","journal-title":"Hypertens Res"},{"key":"1848_CR20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","volume":"43","author":"H Kai","year":"2020","unstructured":"Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648\u201354.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01848-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:48:27Z","timestamp":1779778107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01848-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01848-8","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}